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ANALYSIS

How do psychiatric drugs work?
Joanna Moncrieff and David Cohen argue that changing our view of the action of psychiatric
drugs would help patients to become more involved with decisions about treatment

Assumptions about mode of action
The widespread use of psychiatric drugs is jus
tified by the idea that they work by correcting,
or helping to correct, underlying biological
abnormalities that produce particular psy
chiatric symptoms. We have called this view
the disease centred model of psychiatric drug
action (table). Most drugs used in medicine
can be understood as working according to
a disease centred model—even analgesics, for
example, work by acting on the physiological
mechanisms that produce pain. In psychia
try, the disease centred model is reflected in
the names of the major drug classes: antide
pressants are believed to reverse biochemi
cal pathways that give rise to symptoms of
depression and antipsychotics are thought to
act on mechanisms that produce psychotic
symptoms. From this viewpoint, the therapeu
tic actions of drugs (their actions on disease
processes) can be distinguished from other
effects, accordingly termed side effects.
An alternative, drug centred model of drug
action, stresses that psychiatric drugs are,
first and foremost, psychoactive drugs. They
induce complex, varied, often unpredictable
physical and mental states that patients typi
cally experience as global, rather than distinct
therapeutic effects and side effects (table).
Drugs may be useful because some altered
states can suppress the manifestations of cer
tain mental disorders.
The disease centred model of drug action
developed in the 1950s and 1960s and replaced
a drug centred understanding of how psychi
atric drugs worked.1 For example, the early
investigators of neuroleptic or antipsychotic
drugs suggested that they worked by inducing

a neurological syndrome consisting of physi
cal restriction and mental symptoms such
as cognitive slowing, apathy, and emotional
flattening, which resembled Parkinson’s dis
ease.2 These effects also reduced the intensity
of psychotic symptoms. Thus, extrapyramidal
effects, and their con
joined mental effects,
were not regarded
as side effects but as
the mechanism by
which the drugs pro
duced their intended
outcome.3
Inducing overt
parkinsonism has
long been thought
unnecessary to pro
duce a therapeutic
effect, yet there has
been little consider
ation of the mental
alterations produced
by neuroleptic drugs
and just how these
might interact with
psychotic symp
toms. Some modern
commentators have
suggested that the
emotional indifference induced by neurolep
tics accounts for their therapeutic effects,4 and
empirical research supports this position.5
Overall, the drug centred model suggests
looking more closely at how psychological
alterations produced by psychiatric drugs
interact with the experiences of distress and
psychosocial disability that lead people to seek
clinical help.6
Evidence on psychiatric drug action
Both models help clarify possible mecha
nisms of drug action and need not be mutu
ally exclusive. However, the neglect of the
psychoactive effects of psychiatric drugs has
made it difficult to establish disease specific
actions. For example, placebo controlled tri
als are not designed to distinguish whether
observed outcomes occur because of the
drug’s action on an underlying pathological
process or as a consequence of being in an
altered state. Psychoactive effects, including
sedation, psychomotor slowing, activation,
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and altered sense perception, could have an
effect on the symptoms of distress in countless
disorders and be distinguished from effects
associated with inert placebo.6 Any drug with
sedative properties, for example, will modify
disturbances of sleep and arousal found in
many psychiatric
conditions and in
the disorder specific
rating scales used in
clinical trials.
A second dif
ficulty has been a
paucity of realistic
trials that use active
placebos or compare
drugs believed to be
disorder specific
(according to current
diagnostic classifica
tions or theories) with
other drugs known to
exert some psycho
active effects. Early
trials comparing
chlorpromazine and
barbiturates favoured
chlorpromazine, but
comparisons with
benzodiazepines give
mixed results,7 and a trial using opium as a
comparator found no difference.8 However,
although evidence of the superiority of anti
psychotics might imply disease specific effects,
superior effects can also be explained within a
drug centred framework. This view suggests
that the characteristic psychomotor and emo
tional restriction induced by antipsychotics is
more effective at suppressing psychotic agita
tion than other sedatives, as proposed by the
early investigators.2
Drugs not normally considered to be anti
depressants, including antipsychotics, benzo
diazepines, and stimulants, have been found
to have comparable effects to antidepressants
in people with depression.9 Comparisons
of lithium with antipsychotics and benzodi
azepines have not confirmed its superiority to
treat mania or affective psychosis.10 Although
one study suggested some differential effect on
particular symptoms,11 others have not.12
Biochemical aetiological theories such as
the dopamine theory of schizophrenia or
BSIP VEM/SPL

Drugs for psychiatric problems are pre
scribed on the assumption that they mostly
act against neurochemical substrates of dis
orders or symptoms. In this article we ques
tion that assumption, proposing that drugs’
action be viewed rather as producing altered,
drug induced states, a view we have called
the drug centred model of action. We believe
that this view accords better with the avail
able evidence. It may also allow patients to
exercise more control over decisions about
the value of pharmacotherapy, helping to
move mental health treatment in a more
collaborative direction.
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psychosis and the monoamine hypothesis of
depression seem to support a disease centred
view of drug action, although their strongest
support remains the presumed specificity of
drug treatment. Proponents of the dopamine
hypothesis argue that antipsychotics exert their
therapeutic action by correcting an underly
ing dopamine dysregulation.13 However, little
evidence suggests that any abnormality of the
dopamine system is specific to psychosis and
not accounted for by other factors associated
with dopamine activity, such as increased
arousal or stress. That some effective antipsy
chotic drugs such as clozapine have relatively
weak actions on dopamine receptors also
seems to contradict the theory.14
Evidence for the monoamine hypothesis,
which states that antidepressants work by
countering a deficiency of noradrenaline or
serotonin activity, is also questionable. Many
different investigations of the drugs’ metabo
lites and receptors in depressed people and
postmortem examinations have produced no
reliable demonstration of such a deficiency.15
Generally, there have been few attempts to
evaluate the dominant, disease centred expla
nation for drug action in psychiatry because
few people realise that an alternative explana
tion exists.1 The little available evidence does
not yet provide compelling grounds to accept
the disease centred model.

ness, but this has not been confirmed.18 How
they cause suicidal ideation, if they do, is also
not established. Similarly, few data exist about
the subjective effects produced by second
generation antipsychotics, how they differ
from each other, and whether they are simi
lar to the effects produced by older antipsy
chotics. Obviously, this information is crucial
if people are to make informed choices about
whether these drugs are likely to improve
their mental state and what price might be
paid in return.
More comprehensive volunteer studies
are needed to obtain data on the full range
of effects of psychiatric drugs. It is also impor
tant to pay attention to patients’ uncensored
accounts of taking psychiatric drugs, avail
able on the internet, for example. Clinical
trials need to devise ways to explore patients’
experiences more directly than through clini
cians’ diagnoses and symptom rating scales.
Patients’ views also need to be collected after
the drugs have been stopped, since many
effects may be difficult to identify while in a
drug induced state.

Implications for clinical practice
Messages conveyed in information leaflets
and advertising campaigns have persuaded
millions of people that mental disorders are
caused by chemical imbalances that can be
rectified by drugs.19 However, given the
Drug centred model in research
paucity of the evidence, we suggest that pre
There has been little systematic exploration
scribers should not present the drugs they
of the full range of psychoactive and physical
prescribe for mental disorders as disease spe
effects produced by psychiatric drugs. This
cific treatments. Psychiatric drugs might need
information is typically obscured by short
renaming, to avoid the presumption of spe
clinical trials that focus on narrow complaints
cificity built into labels like antidepressants
and outcomes and relegate
and antipsychotics.
other effects to the status of There has been little systematic
The drug centred
side effects.16 There is also exploration of the full range of
model may change
a paucity of research on psychoactive and physical effects attitudes to psychiatric
the often unpredictable, produced by psychiatric drugs
drugs and empower
long term effects of drugs,
patients to be more
the consequences of drug withdrawal, and the
involved in decisions about treatment.
nature of the large black box presently called
Whereas a disease centred model has a builtthe placebo effect.
in assumption that drug treatment is likely to
For example, the nature of the subjec
be physiologically corrective and therefore
tive state induced by taking selective serot
beneficial, a drug centred model, by stress
onin reuptake inhibitors (SSRIs), and how
ing that drugs are extrinsic substances that
it interacts with expectancy effects, remains
alter how the body works, demands that
unclear. Volunteer studies suggest these drugs
the advantages and disadvantages of tak
may have concurrent sedative and activat
ing a drug be carefully weighed up and dis
ing or stimulant effects,17 and some research
tinguished from the effects of treatment in
indicates they reduce emotional responsive
general. Highlighting that psychiatric drugs
1536			

Models of psychiatric drug action
Disease centred model

Drug centred model

Drugs correct an abnormal
brain state

Drugs create an altered
physical and mental state

Therapeutic effects arise
from the action of drugs
on an underlying disease
process

Therapeutic effects are a
consequence of being in an
altered state

Main indication is the
presence of a particular
disease

Indication is the value of
particular drug induced
effects

are psychoactive substances allows people
to judge for themselves what sort of drug
induced effects might help them and what
sort might not. Patients become the ultimate
arbiters of the value of taking a particular
drug and are encouraged to take an active
role in adjusting drug regimens to suit their
needs.
In the short term, for example, the cog
nitive and emotional suppression described
by people who have taken antipsychotic
drugs may bring relief to someone trauma
tised by intense psychotic experiences and
allow people to engage better with the world
around them.20 However, after recovery from
an acute episode, some people may decide
that the costs of continued drug treatment
are not outweighed by the reduction in the
risk of relapse that long term treatment may
produce. According to a drug centred model,
therefore, non- compliance may be a rational
response to the effects of drugs, which pre
scribers need to understand and accommo
date rather than overcome.
People with depression are likely to
respond differently to an offer of a drug
intended to produce an altered state than a
drug said to act on the underlying biological
mechanism of depressive symptoms. Various
psychoactive drugs, such as antipsychotics
and possibly SSRIs, may suppress the expe
rience or expression of emotions, including
feelings of depression, but it seems unlikely
that many people would desire this kind of
effect. On the other hand, some people with
depression may find drugs with sedative
effects, such as benzodiazepines and low dose
tricyclic antidepressants, useful temporarily
to bring relief from troubled sleep, anxiety,
and agitation.
In this way, the drug centred model
provides a rationale for periodic rather
than continuous drug use, to cope with
BMJ | 27 June 2009 | Volume 338
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e xacerbations of symptoms or to palliate
stressful environmental events and avoid the
harm associated with long term use. It ques
tions the use of complex drug cocktails, com
monly prescribed in the United States, for
example, based on the presumed fit between
different drugs and multiple diagnoses given
to a patient. It also allows doctors, patients,
and people who know patients to properly
monitor the full consequences of drug treat
ment and engage in an ongoing dialogue
about how it compares with alternative
interventions.
Medicine, as a whole, has started to rec
ognise the importance of involving patients
in decisions about their care. By highlighting
the nature of psychiatric drugs as psychoac
tive substances that produce altered states,
the drug centred model may enable patients
to participate more equally in the process
of evaluating the likely effect of drug treat
ment in their particular situation. A drug
centred model also imposes a duty on the
psychiatric research community to produce
relevant, unbiased information about the
range of effects that psychiatric drugs exert
on thought, emotion, and all bodily systems,
both during short term and long term use. At
present, the influence of the disease centred
model keeps the full range of effects of many
drugs obscured, and hence neither doctors
nor patients can make properly informed
decisions about the risks and benefits of
using them.
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Statistical question
Number needed to treat
a

Case report
A case of secondary amenorrhoea
1 This patient has Asherman’s syndrome, a condition
characterised by scarring of the uterine cavity.
2 Hysteroscopy is recommended in a patient with
these symptoms.
3 Hysteroscopically directed division of adhesions is
the optimum treatment.
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Picture Quiz
A woman with tuberous sclerosis and acute onset
right sided abdominal pain
1 Bilateral renal angiomyolipoma is the most likely cause of the masses seen in
the figures. The computed tomography scans show that the renal parenchyma is
abnormal, with enhancing vessels and low attenuation fat representing vascular
and fatty components, respectively, within the angiomyolipoma.
2 The patient’s symptoms are caused by acute haemorrhage. Her physical condition
and the imaging findings can be explained by haemorrhage from the vascular
component of the angiomyolipoma.
3 Selective renal arterial embolisation is the treatment of choice. Embolisation not
only stops further bleeding but is less invasive than surgery and spares functioning
renal tissue. After our patient was scanned, she immediately went to angiography
for embolisation.
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